10th CAR-TCR SUMMIT

10th CAR-TCR SUMMIT, here wecome!

Cellistic is excited to join the 10th CAR-TCR Summit, with Wesley Tidball, MBA, from our Business Development team representing us. As the field advances rapidly, overcoming challenges in scaling and manufacturing CAR-T and TCR therapies is critical—and we look forward to partnering with innovators driving these next-generation immunotherapies forward.

Addressing Key Challenges in CAR-T and TCR Therapy Development

Manufacturing CAR-T and TCR therapies at clinical and commercial scale demands precise gene editing, robust cell expansion, and compliance with GMP standards—all while controlling costs and timelines. These challenges must be met to deliver safe, effective treatments to patients worldwide.

Cellistic’s Integrated CDMO and Technology Solutions

Cellistic combines expert CDMO services with our proprietary Pulse™ and Echo™ platforms to support scalable, GMP-compliant production of iPSC-derived immune effector cells engineered for CAR and TCR applications. Using our STAR-CRISPR™ technology at the iPSC stage, we enable streamlined development from reprogramming through differentiation, expansion, and final clinical product manufacturing.

Connect with Wes Tidball at the summit to discover our latest applications and collaborative work advancing CAR and TCR therapies.

At Cellistic, we deliver effective solutions to meet these challenges through our integrated Pulse™ and Echo™ platforms, which enable the scalable development and GMP manufacturing of iPSC-based cell therapies. Our comprehensive end-to-end solution encompasses all stages, from iPSC reprogramming and gene editing—utilizing our proprietary STAR-CRISPR™ technology—to differentiation and characterized expansion, all the way to the clinical cell therapy product.

Book a meeting with Wesley Tidball